CN113840842A - 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层 - Google Patents

利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层 Download PDF

Info

Publication number
CN113840842A
CN113840842A CN202080017112.1A CN202080017112A CN113840842A CN 113840842 A CN113840842 A CN 113840842A CN 202080017112 A CN202080017112 A CN 202080017112A CN 113840842 A CN113840842 A CN 113840842A
Authority
CN
China
Prior art keywords
egfr
cancer
met
seq
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080017112.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·摩尔
S·维贾亚勒格文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CN113840842A publication Critical patent/CN113840842A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080017112.1A 2019-02-26 2020-02-24 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层 Pending CN113840842A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810716P 2019-02-26 2019-02-26
US62/810716 2019-02-26
US201962930190P 2019-11-04 2019-11-04
US62/930190 2019-11-04
PCT/IB2020/051559 WO2020174370A2 (en) 2019-02-26 2020-02-24 Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies

Publications (1)

Publication Number Publication Date
CN113840842A true CN113840842A (zh) 2021-12-24

Family

ID=72142314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017112.1A Pending CN113840842A (zh) 2019-02-26 2020-02-24 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层

Country Status (16)

Country Link
US (3) US11459391B2 (https=)
EP (1) EP3931224A4 (https=)
JP (3) JP7703448B2 (https=)
KR (1) KR20210132117A (https=)
CN (1) CN113840842A (https=)
AU (1) AU2020229467A1 (https=)
BR (1) BR112021016149A2 (https=)
CA (1) CA3131654A1 (https=)
IL (1) IL285718A (https=)
JO (1) JOP20210233A1 (https=)
MA (1) MA55089A (https=)
MX (1) MX2021010265A (https=)
NZ (1) NZ778579A (https=)
PH (1) PH12021552030A1 (https=)
SG (1) SG11202108311RA (https=)
WO (1) WO2020174370A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222671A1 (zh) * 2023-04-24 2024-10-31 正大天晴药业集团股份有限公司 靶向c-Met的多特异性抗体
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
SG11202111120VA (en) * 2019-04-17 2021-11-29 Univ Texas Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
WO2020230091A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
AU2020275272A1 (en) * 2019-05-14 2021-12-02 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
PH12022552076A1 (en) 2020-02-12 2023-11-29 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS
IL300854A (en) 2020-08-25 2023-04-01 Janssen Biotech Inc Treatment of non-small cell lung cancer with EGFR mutations
IL305700A (en) * 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations
TW202317635A (zh) * 2021-07-14 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｈｇｆｒ和ｅｇｆｒ的抗原結合分子及其醫藥用途
KR20240051145A (ko) * 2021-07-29 2024-04-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Kras 돌연변이 암의 치료를 위한 방법 및 조성물
KR102793991B1 (ko) 2021-10-06 2025-04-09 주식회사 엘지에너지솔루션 태양광 시스템과 연계하는 에너지 저장 시스템 및 에너지 저장 시스템의 제어 방법
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
CN120882752A (zh) * 2023-03-13 2025-10-31 詹森生物科技公司 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226455A1 (en) * 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
US20140141000A1 (en) * 2012-11-21 2014-05-22 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
CN107949401A (zh) * 2015-05-12 2018-04-20 拜奥文斯瑞有限公司 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
CN101501211A (zh) 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
CN101193905B (zh) 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
MX2007009963A (es) 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
WO2006104911A2 (en) 2005-03-25 2006-10-05 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US8962808B2 (en) 2010-05-05 2015-02-24 The Research Foundation For The State University Of New York EGFR-related polypeptides and methods of use
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
CN107266577B (zh) 2011-10-11 2022-09-13 弗·哈夫曼-拉罗切有限公司 双特异性抗体的改进的组装
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US20170275367A1 (en) * 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
WO2015043614A1 (en) * 2013-09-26 2015-04-02 Biontech Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
WO2015188777A1 (en) 2014-06-12 2015-12-17 Shanghai Fochon Pharmaceutical Co Ltd Certain protein kinase inhibitors
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
CA2967379A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
CA3002957A1 (en) 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
JP2018535242A (ja) 2015-11-30 2018-11-29 メディミューン，エルエルシー 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比
EP3453392B1 (en) 2016-05-17 2025-10-22 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired egfr-tki resistance
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
HUE054571T2 (hu) 2016-09-14 2021-09-28 Merck Patent Gmbh Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
WO2018152634A1 (en) 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
CA3110658A1 (en) 2018-09-04 2020-03-19 Rain Therapeutics Inc. Compounds, compositions and methods for treating or preventing her-driven cancers
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
EP3946293A4 (en) 2019-03-29 2023-05-03 Board of Regents, The University of Texas System COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS
SG11202111120VA (en) 2019-04-17 2021-11-29 Univ Texas Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
EP3955928A4 (en) 2019-04-17 2023-05-31 Board of Regents, The University of Texas System COMPOUNDS HAVING ANTITUMORIC ACTIVITY AGAINST CANCER CELLS WITH TYROSINE KINAS INHIBITOR-RESISTANT EGFR MUTATIONS
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
TW202309094A (zh) * 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090226455A1 (en) * 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
US20140141000A1 (en) * 2012-11-21 2014-05-22 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN104955838A (zh) * 2012-11-21 2015-09-30 詹森生物科技公司 双特异性EGFR/c-Met抗体
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
CN107949401A (zh) * 2015-05-12 2018-04-20 拜奥文斯瑞有限公司 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHERI L MOORES ET AL.: ""A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors"", 《CANCER RES 》, vol. 76, no. 13, 1 July 2016 (2016-07-01), pages 3942 - 3953, XP055431654, DOI: 10.1158/0008-5472.CAN-15-2833 *
姜文奇: "《肿瘤生物治疗学》", vol. 1, 30 April 2006, 广东科技出版社, pages: 101 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222671A1 (zh) * 2023-04-24 2024-10-31 正大天晴药业集团股份有限公司 靶向c-Met的多特异性抗体
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途

Also Published As

Publication number Publication date
US12215161B2 (en) 2025-02-04
EP3931224A4 (en) 2023-03-01
JP2022521610A (ja) 2022-04-11
IL285718A (en) 2021-10-31
JOP20210233A1 (ar) 2023-01-30
WO2020174370A3 (en) 2020-12-03
AU2020229467A1 (en) 2021-08-12
JP2025084739A (ja) 2025-06-03
US20200270351A1 (en) 2020-08-27
US20250236675A1 (en) 2025-07-24
SG11202108311RA (en) 2021-09-29
MX2021010265A (es) 2021-09-23
WO2020174370A2 (en) 2020-09-03
JP7703448B2 (ja) 2025-07-07
EP3931224A2 (en) 2022-01-05
JP2024153659A (ja) 2024-10-29
MA55089A (fr) 2022-01-05
US20230130600A1 (en) 2023-04-27
PH12021552030A1 (en) 2022-08-15
US11459391B2 (en) 2022-10-04
CA3131654A1 (en) 2020-09-03
KR20210132117A (ko) 2021-11-03
BR112021016149A2 (pt) 2021-10-13
NZ778579A (en) 2026-03-27

Similar Documents

Publication Publication Date Title
US12215161B2 (en) Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
AU2016281717B2 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
EP2523976B1 (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
CN106999583A (zh) 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
JP2017501167A (ja) Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
JP2018532383A (ja) ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
EP3938396A1 (en) Anti-icos antibodies for the treatment of cancer
CN111051346A (zh) 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20230053686A (ko) Egfr 돌연변이를 갖는 비소세포 폐암의 치료
CN117321418A (zh) 癌症生物标志物及其使用方法
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
JP2022532519A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
KR20260013482A (ko) 비-소세포 폐암(nsclc)의 치료 방법
EP3491022B1 (en) Antibodies targeting tumor associated macrophages and uses thereof
US20240228634A1 (en) Treatment of Cancers Lacking EGFR- Activating Mutations
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
HK40128024A (zh) 双特异性抗egfr/c-met抗体和抗pd-1抗体的组合疗法
HK1241729A1 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
HK1230525A1 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination